ImThera Medical has developed a novel neurostimulation medical device for the treatment of Obstructive Sleep Apnea (OSA).
Through targeted tongue-muscle stimulation, ImThera's sleep apnea implant delivers muscle tone to key tongue muscles during sleep, opening the upper airway and substantially reducing or eliminating OSA events.
The U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) for the THN3 Clinical Study, which will evaluate the safety and effectiveness of this therapy for moderate to severe obstructive sleep apnea in individuals who are unable to comply or unwilling to try PAP therapy or other OSA treatments. Find out more about the study >>>
Caution: Investigational device, limited by United States law to investigational use